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ABSTRACT  
Ion-exchange chromatography (IEC) is the most frequently used technique to purify proteins and therefore, plays an 
important role in process development for therapeutical proteins. To improve the purification using ion-exchange 
chromatography, adequate characterization of adsorption isotherms is obligatory. The Elution by Characteristic Point 
method (ECP) can be used to determine adsorption isotherms applying only minor amounts of sample material to the 
chromatography column. Here, the applicability of the extended ECP method to determine adsorption isotherms of the 
model protein bovine serum albumin (BSA) using bovine hemoglobin (bHb) as tracer substance to quantify all non-
idealities of the system is shown. The resulting isotherm was validated using the static batch approach. In the next step, 
the gained knowledge is used to measure isotherms of Labyrinthopeptins A1 and A2, which show promising activity 
against retroviruses like herpes simplex virus or human immunodeficiency virus. 
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INTRODUCTION 
The market for biopharmaceuticals is still growing, 
reaching the highest number of new approvals since 
1996 in 2017 [Morrison, 2018]. In the same year sales 
of biopharmaceuticals reached 188 billion US$ with 
monoclonal antibodies alone combining for 65.6% of 
total sales [Morrison, 2018; Walsh, 2018].  
General production schemes for biopharmaceuticals 
consist of the production of the target product using 
mammalian cells or microorganisms and subsequent 
downstream processing. Chromatography is the most 
frequently used technique for the purification of 
biopharmaceuticals. For industrial applications, 45% of 
all chromatographic purification steps are ion-exchange 
chromatography steps [Karlsson, 2011]. This implies 
the important role IEC plays in the production of 
biopharmaceuticals. However, chromatographic 
purification processes are still expensive making 
downstream processing with up to 80% of the overall 
process costs the most cost-intensive part in the 
production of biopharmaceuticals [Roque, 2004]. 
Hence, one should focus on finding efficient and 
therefore economic operation points for a specific 
chromatographic separation task.  
Lanthipeptides, post-translationally modified peptides 
with a characteristic polycyclic structure, are such a 
promising group of biopharmaceuticals showing high 
potential against retroviruses in vitro [Meidl, 2010], but 
with large differences in their potential [Férir, 2013]. 
For example, Labyrinthopeptin A1 is 10-fold more 
potent against herpes simplex virus and human 
immunodeficiency virus than Labyrinthopeptin A2 
making a separation of these peptides desireable.  IEC 
is a very promising separation technique as shown for 
nisin, another prominent lanthipeptide [Abts, 2010]. 
A deep understanding of the interaction between 
peptides and stationary phase under various process 
conditions is needed to account for variations in the 
fermentation broth fed into the downstream processing. 
Hence, the characterization of adsorption isotherms is 
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essential for process development. While a variety of 
methods has been described in literature to determine 
adsorption isotherms experimentally, only the dynamic 
so-called Elution by Characteristic Point (ECP) method 
offers the possibility to gain complete isotherm data 
with just one experiment leading to smallest 
consumption of substance [Seidel-Morgenstern, 2004]. 
This low demand is a crucial advantage as the targeted 
peptides A1 and A2 are not commercially available but 
have to be produced and purified specifically for 
adsorption experiments. One of the most limiting 
factors for ECP, especially in early stage development, 
is the need for a high number of theoretical stages to 
provide accurate isotherm data. This limitation was 
recently overcome by an Extended Elution by 
Characteristic Point (EECP) method, where non-
idealities of the system, e.g., convection, dispersion or 
low number of theoretical plates are quantified by 
using a specific marker substance [Hartig 2015]. 
In this work, EECP is transferred to the system of 
labyrinthopeptins and ion-exchange resins. To this end, 
the cheap and easy available proteins BSA and bHb are 
used as model substances to characterize the required 
process conditions to generate adsorption isotherms 
and to understand occurring problems and limitations. 
Then, the knowledge is used to measure adsorption 
isotherms of labyrinthopeptins on ion-exchange resins. 
THEORY 
This section gives a brief summary of the derivation 
and use of EECP [Hartig, 2015]. The standard 
equilibrium model of chromatography neglects 
dispersion and assumes instantaneous adsorption 
equilibrium between the bulk fluid phase and the 
particle at every axial position. While the equilibrium 
assumption can be fulfilled by using low flow rates and 
small particle diameters, neglecting the axial dispersion 
leads to the need of a high number of theoretical plates 
in classical ECP. In contrast, EECP method assumes 
that all non-idealities, e.g., non-rectangular injection 
profile and axial dispersion, are linearly independent 
from the effects of adsorption and can be determined 
by a tracer injection. Hence, all non-ideal influences 
are lumped into a concentration-dependent system dead 
volume VS that is subtracted from the retention volume 
of the adsorptive VR. Then, the loading is calculated 
using this corrected retention volume (VR – VS): 
𝑞ሺ𝑐௜ሻ ൌ ௖೔,೘ೌೣ௠ಲ೏  ׬ ቀ𝑉ோ൫?̃?௜
°൯ െ 𝑉ௌ൫?̃?௜°൯ቁ 𝑑൫?̃?௜°൯௖೔
°
଴  (1) 
𝑐௜° ൌ ௖೔௖೔,೘ೌೣ 𝑐௝
° ൌ ௖ೕ௖ೕ,೘ೌೣ (2)
It is worth stressing that 𝑐௜° and 𝑐௝° represent the 
normalized concentrations of the adsorbing and the 
tracer substance, respectively. Both concentration 
profiles are normalized for comparability.  
RESULTS AND DISCUSSION 
As discussed in the last section, the application of 
EECP requires the flow rate to be small enough to 
allow for an establishment of equilibrium between bulk 
liquid and stationary phase. Hence, Fig. 1 shows the 
influence of the superficial velocity on the determined 
Henry coefficient for BSA vs bHb defined by: 
𝐻 ൌ ௏ಳೄಲି௏್ಹ್௠ಲ೏ (3)
The superficial velocity was corrected for a decreased 
available cross section due to partial blocking of the 
bed as determined by total porosity measurements 
using glucose as tracer (see [Hartig, 2017] for further 
details on porosity measurement). It becomes obvious 
that the superficial velocity should not exceed 
10 mm/min to allow neglecting kinetic effects. 
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Figure 1: Henry coefficient between BSA and bHb on 
Q Sepharose FF at 25 °C in 20 mM sodium phosphate buffer 
(ph 7) determined by retention time of peak maximum at 
varying superficial velocity. Concentration of BSA and bHb 
was approximately 7 µM and 10 µM, respectively. 
Volumetric flow was varied between 25 µL/min and 
400 µL/min. Data from [Hartig, 2017]. 
Besides the use of a feasible small flow rate, two 
additional factors had to be included to determine BSA 
isotherms. First, only 35% of the expected total 
porosity were measured leading to a correction of the 
mass of adsorbent to only 35% of the mass weighted 
into the column. Second, bHb showed a measureable 
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adsorption at the applied conditions. Hence, the slope 
of the bHb isotherm was determined in batch 
experiments (data not shown) and this slope was added 
to the BSA isotherm. With these corrections, the 
adsorption isotherms of BSA were determined. This is 
exemplary shown at 25 °C in Fig. 2.  
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Figure 2: Adsorption isotherm of BSA at 25 °C in 20 mM 
sodium phosphate buffer (ph 7), bHb was used as tracer. 
Data from [Hartig, 2017]. 
A good agreement between the results of batch and 
EECP measurements can be seen. Size exclusion 
effects that could not be totally ruled out due to the 
different shape of BSA and bHb might cause the small 
deviation at higher concentrations. This stresses the 
importance to find feasible tracers for the particular 
adsorptive. With respect to used material, static 
adsorption experiments needed about 37 mg BSA 
whereas one EECP isotherm was measured with only 
12 mg BSA. Although the calibration of the detector 
and the determination of a feasible flow rate lead to an 
additional consumption of about 25 mg BSA, 
recalibration is not necessary for the investigation of 
other conditions like different buffer concentrations or 
temperatures. Overall, EECP might reduce the material 
needed by nearly 70% for all further isotherms 
compared to batch. 
The behavior of the small peptides Labyrinthopeptin 
A1 and A2, having molecular masses of 2.072 kDa and 
1.922 kDa, respectively, might differ notably from the 
larger protein BSA (66.5 kDa) due to increased 
diffusion coefficient but also increased diffusion path 
inside the porous matrix. Hence, adjustment of the 
experimental conditions is mandatory to fulfill the 
equilibrium assumption before conducting EECP 
measurements. As indicated in Fig. 3, superficial 
velocities below 10 mm/min should be chosen for 
Labyrinthopeptin A1 to ensure establishment of 
equilibrium. It is worth noting that the similar value 
compared to BSA should rather be seen as coincidence 
since the impact of smaller molecule size on diffusion 
kinetic is complex. The retention coefficient can be 
calculated using the retention volume at the peak 
maximum: 
𝑘ᇱ ൌ ௏ೃି௏೅௏೅  (4)
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Figure 3: Retention coefficient of Labyrinthopeptin A1 on 
Q Sepharose FF at 25 °C in 20 mM Bis-Tris buffer (ph 7) 
with 200 mM sodium chloride at varying superficial 
velocities. 
CONCLUSION AND OUTLOOK 
The extended Elution by Characteristic Point method is 
a rapid approach to determine adsorption isotherms 
consuming only small amounts of sample material. 
This was successfully shown for model proteins BSA 
and bHb on Q Sepharose FF, where a good correlation 
to the well-established batch method can be seen. 
Since the method has been established for the model 
proteins BSA and bHb and crucial process parameters 
for the determination of adsorption isotherms for 
labyrinthopeptins on Q Sepharose FF have been 
characterized, isotherm data for A1 and A2 will be 
generated in future experiments. 
NOMENCLATURE 
c concentration, mg/L 
k’ retention coefficient, 1 
m mass, mg 
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q loading of adsorbent, mg/mg 
V volume, mL 
BSA bovine serum albumin 
bHb bovine hemoglobin 
ECP elution by characteristic point 
IEC ion-exchange chromatography 
SUBSCRIPT 
° normalized 
0 initial 
A1 Labyrinthopeptin A1 
Ad adsorbent 
i solute 
j marker 
max maximum 
R retention 
T total 
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